Influence
May 1, 2024

Mobile Critical Care Recovery Program for Survivors of Acute Respiratory Failure: A Randomized Clinical Trial

Dr. Babar Khan on All IN

Published in JAMA Network Open. Here is a link to the article.

Regenstrief Institute authors: Babar Khan, M.D., M.S., Sikandar H. Khan, D.O., M.D., Malaz Boustani, M.D., MPH, Frederick W. Unverzagt, PhD, (affiliated scientist), Sujuan Gao, PhD, (affiliated scientist)

Abstract

Importance: Over 50% of Acute Respiratory Failure (ARF) survivors experience cognitive, physical, and psychological impairments that negatively impact their quality of life (QOL).

Objective: To evaluate the efficacy of a post-intensive care unit (ICU) program, the Mobile Critical Care Recovery Program (m-CCRP) consisting of a nurse care coordinator supported by an interdisciplinary team, in improving the QOL of ARF survivors.

Design, setting, and participants: This randomized clinical trial with concealed outcome assessments among ARF survivors was conducted from March 1, 2017, to April 30, 2022, with a 12-month follow-up. Patients were admitted to the ICU services of 4 Indiana hospitals (1 community, 1 county, 2 academic), affiliated with the Indiana University School of Medicine.

Intervention: A 12-month nurse-led collaborative care intervention (m-CCRP) supported by an interdisciplinary group of clinicians (2 intensivists, 1 geriatrician, 1 ICU nurse, and 1 neuropsychologist) was compared with a telephone-based control. The intervention comprised longitudinal symptom monitoring coupled with nurse-delivered care protocols targeting cognition, physical function, personal care, mobility, sleep disturbances, pain, depression, anxiety, agitation or aggression, delusions or hallucinations, stress and physical health, legal and financial needs, and medication adherence.

Main outcomes and measures: The primary outcome was QOL as measured by the 36-item Medical Outcomes Study Short Form Health Survey (SF-36) physical component summary (PCS) and mental component summary (MCS), with scores on each component ranging from 0-100, and higher scores indicating better health status.

Results: In an intention-to-treat analysis among 466 ARF survivors (mean [SD] age, 56.1 [14.4] years; 250 [53.6%] female; 233 assigned to each group), the m-CCRP intervention for 12 months did not significantly improve the QOL compared with the control group (estimated difference in change from baseline between m-CCRP and control group: 1.61 [95% CI, -1.06 to 4.29] for SF-36 PCS; -2.50 [95% CI, -5.29 to 0.30] for SF-36 MCS. Compared with the control group, the rates of hospitalization were higher in the m-CCRP group (117 [50.2%] vs 95 [40.8%]; P = .04), whereas the 12-month mortality rates were not statistically significantly lower (24 [10.3%] vs 38 [16.3%]; P = .05).

Conclusions and relevance: Findings from this randomized clinical trial indicated that a nurse-led 12-month comprehensive interdisciplinary care intervention did not significantly improve the QOL of ARF survivors after ICU hospitalization. These results suggest that further research is needed to identify specific patient groups who could benefit from tailored post-ICU interventions.

Authors:

Babar A. Khan1,2,3,4, Anthony J. Perkins5, Sikandar Hayat Khan1,2,3, Frederick W. Unverzagt6, Sue Lasiter7, Sujuan Gao5, Sophia Wang6, Ben L. Zarzaur8, Omar Rahman1, Ahmed Eltarras1, Hadi Qureshi2, Malaz A. Boustani1,2,3,4

Affiliations:

1Department of Medicine, Indiana University School of Medicine, Indianapolis.

2Indiana University Center for Aging Research, Indianapolis.

3Regenstrief Institute Inc, Indianapolis, Indiana.

4Indiana University Center for Health Innovation and Implementation Science, Indiana Clinical and Translational Sciences Institute, Indianapolis.

5Department of Biostatistics, Indiana University School of Medicine, Indianapolis.

6Department of Psychiatry, Indiana University School of Medicine, Indianapolis.

7School of Nursing and Health Sciences, University of Missouri, Kansas City.

8Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison.

Partners

Related News

Malaz Boustani, M.D., MPH, Paul Dexter, M.D., Zina Ben Miled, PhD, M.S.

Dementia risk prediction: Zero-minute assessment at less than a dollar cost

Risk detection is important for care management and may alter course of the disease INDIANAPOLIS – A new study

Joshua Vest, PhD, MPH

Regenstrief Institute researcher appointed associate dean for research at IU Indianapolis Fairbanks School of Public Health

Regenstrief Institute Research Scientist Joshua Vest, PhD, MPH, has been appointed associate dean for research at the Indiana University

Alzheimer Disease as a Clinical-Biological Construct-An International Working Group Recommendation

Title: Alzheimer Disease as a Clinical-Biological Construct-An International Working Group Recommendation Published in the journal JAMA Neurology. Here is

AMIA honors Regenstrief researcher with leadership award

Regenstrief Institute Research Scientist Titus K. Schleyer, DMD, PhD, was awarded a 2024 leadership award by the American Medical